Headlines about Akers Biosciences (NASDAQ:AKER) have been trending somewhat positive on Monday, according to Accern. Accern ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akers Biosciences earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 45.8889290832449 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Akers Biosciences (NASDAQ:AKER) remained flat at $$0.46 during midday trading on Monday. 1,018,600 shares of the company were exchanged, compared to its average volume of 184,088. Akers Biosciences has a twelve month low of $0.36 and a twelve month high of $2.90.
Akers Biosciences (NASDAQ:AKER) last announced its earnings results on Wednesday, November 15th. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter. The business had revenue of $0.68 million for the quarter. Akers Biosciences had a negative net margin of 134.31% and a negative return on equity of 94.44%.
Separately, ValuEngine upgraded shares of Akers Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, December 1st.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/11/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-akers-biosciences-aker-stock-price.html.
Akers Biosciences Company Profile
Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The companys marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.
Receive News & Ratings for Akers Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.